安旭生物（688075）披露2025年年度业绩预告，1月30日股价下跌0.57%

Core Viewpoint - Hangzhou Anxu Biotechnology Co., Ltd. is expected to experience a significant decline in net profit for the year 2025, primarily due to increased tariffs, rising operating costs, and other financial factors [1] Financial Performance - The company forecasts a net profit attributable to shareholders of between 71 million yuan and 85 million yuan for 2025, representing a year-on-year decrease of 55.80% to 63.08% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 13 million yuan and 15.6 million yuan, reflecting a year-on-year decline of 58.84% to 65.70% [1] Factors Influencing Performance - The decline in performance is attributed to several factors, including: - Increased tariffs from the United States leading to reduced orders - Rising operating costs - Exchange rate fluctuations and foreign exchange losses - Decreased interest income - Increased asset depreciation and amortization [1] Strategic Investments - The company is increasing its investment in new technology platforms and expanding its overseas market presence, which has resulted in higher expenses [1]